Atonomics A/S announced today that it has achieved an important milestone related to a defined set of performance criteria for a Troponin I assay on the new Atolyzer® system.
Since entering an equity investment agreement with Beckman Coulter in May of last year to advance the Atolyzer® within cardiac testing, the company has worked diligently to deliver relevant Troponin I performance data.
"We are pleased to achieve this milestone," said Thomas Warthoe, Atonomics' CEO. "Troponin I is one of the most difficult assays to transfer to a near-patient system and still deliver data that are comparable to what the physicians get from the central laboratory; we believe the Atolyzer® has the potential to allow physicians in the future to continue to safely implement data from a near patient system."
"We expect that this recent and significant achievement will generate appropriate interest from Industry in order to reach the full potential of the Atolyzer® platform," said Ashok Dhanrajgir, Chairman of Atonomics board of directors and senior partner with Inventages Venture Capital
Atonomics' majority shareholders are Inventages Venture Capital, Sunstone Capital, NeuroSearch A/S, and Beckman Coulter.